Black Diamond Therapeutics (BDTX) vs PolyPid (PYPD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PolyPid (PYPD) has outperformed Black Diamond Therapeutics (BDTX) over the past year, gaining 42.9% versus a loss of 54.6%. Over five years, BDTX leads with a -77.9% price change compared with -97.8% for PYPD. Black Diamond Therapeutics is the larger company by market cap ($103.7 million vs $99.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDTX | PYPD |
|---|---|---|
| Share price | $1.81 | $4.90 |
| Market cap | $103.72M | $99.53M |
| 1-day change | -1.09% | -1.01% |
| YTD return | -25.51% | +12.90% |
| 1-year return | -54.64% | +42.86% |
| 5-year return | -77.87% | -97.83% |
| EPS (TTM) | $-0.75 | $-1.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.94 | $5.73 |
| 52-week low | $1.60 | $3.06 |
| Distance from 52-week high | -63.36% | -14.49% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +452.49% | +139.80% |
| Average volume | 624.32K | 176.73K |
| Shares outstanding | 57.30M | 20.31M |
| Employees | 21 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PYPD has outperformed BDTX by 97.5 percentage points over the past year.
About Black Diamond Therapeutics
BDTX stock →Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees
About PolyPid
PYPD stock →PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
Health Care · Medical/Dental Instruments · 69 employees
BDTX vs PYPD FAQ
Which is bigger, Black Diamond Therapeutics or PolyPid?
Black Diamond Therapeutics (BDTX) is larger, with a market capitalization of $103.72M compared with $99.53M for PolyPid (PYPD).
Which stock has performed better over the past year, BDTX or PYPD?
PYPD returned +42.86% over the past 12 months, compared with -54.64% for BDTX (price return, excluding dividends). Past performance does not predict future results.
Are Black Diamond Therapeutics and PolyPid in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Black Diamond Therapeutics and Medical/Dental Instruments for PolyPid.